Skip to Content

Rule

New Animal Drugs; Withdrawal of Approval of New Animal Drug Applications

A Rule by the Food and Drug Administration on 12/27/2016

Published Document: 2016-31082 (81 FR 95025)

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings

Document headings vary by document type but may contain the following:

  1. the agency or agencies that issued and signed a document
  2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
  3. the agency docket number / agency internal file number
  4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions

See the Document Drafting Handbook for more details.

Department of Health and Human Services
Food and Drug Administration
  1. 21 CFR Part 558
  2. [Docket No. FDA-2016-N-0002]

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notification of withdrawal.

SUMMARY:

The Food and Drug Administration (FDA) is withdrawing approval of 11 new animal drug applications (NADAs) and 4 abbreviated new animal drug applications (ANADAs). These withdrawals of approval of NADAs and ANADAs for antimicrobial drugs of importance to human medicine that are administered to food-producing animals in medicated feed are being made because the products are no longer being manufactured or marketed. These actions are consistent with the FDA Center for Veterinary Medicine's initiative for the Judicious Use of Antimicrobials.

DATES:

Withdrawal of approval is effective December 30, 2016.

FOR FURTHER INFORMATION CONTACT:

Sujaya Dessai, Center for Veterinary Medicine (HFV-212), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5761, .

SUPPLEMENTARY INFORMATION:

FDA is withdrawing approval of 11 NADAs and 4 ANADAs. These applications were identified as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209,” December 2013 ( http://www.fda.gov/​downloads/​AnimalVeterinary/​GuidanceComplianceEnforcement/​GuidanceforIndustry/​UCM299624.pdf). Their withdrawal of approval is consistent with the FDA Center for Veterinary Medicine's initiative for the Judicious Use of Antimicrobials.

Approval of the following applications for new animal drugs administered in medicated feed is being voluntarily withdrawn at the sponsors' requests because these products are no longer manufactured or marketed:

File No. Product name Sponsor
034-085 LINCOMIX (lincomycin hydrochloride monohydrate) Type A Medicated Article Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.
035-287 OM-5 Premix (oleandomycin) Type A Medicated Article Phibro Animal Health Corp., GlenPointe Centre East, 3d Floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, NJ 07666.
046-668 Penicillin G Procaine 50% Type A Medicated Article Phibro Animal Health Corp., GlenPointe Centre East, 3d Floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, NJ 07666.
091-668 CHLORMAX-SP 500 (chlortetracycline, sulfamethazine, penicillin G procaine) Type A Medicated Article Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.
108-116 LINCOMIX (lincomycin)/NICARB (nicarbazin) Phibro Animal Health Corp., GlenPointe Centre East, 3d Floor, 300 Frank W. Burr Blvd., Suite 21, Teaneck, NJ 07666.
133-334 Virginiamycin Type A Medicated Article Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.
139-473 STAFAC (virginiamycin)/STENEROL (halofuginone hydrobromide) Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
140-340 LINCOMIX (lincomycin)/STENOROL (halofuginone hydrobromide) Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
140-443 HYGROMIX 1.6 (hygromycin B) Type A Medicated Article Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007.
140-947 LINCOMIX (lincomycin)/MAXIBAN (narasin and nicarbazin) Elanco US, Inc., 2500 Innovation Way, Greenfield, IN 46140.
141-090 STAFAC (virginiamycin)/CLINICOX (diclazuril) Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
200-171 LINCOMIX (lincomycin)/NICARMIX (nicarbazin) Planalquimica Industrial Ltda., Rua das Magnolias nr. 2405, Jardim das Bandeiras, CEP 13053-120, Campinas, Sao Paulo, Brazil.
200-569 TYLAN (tylosin)/SACOX (salinomycin) Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
200-570 TYLOVET 100 (tylosin)/BIO-COX (salinomycin) Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.
200-580 TYLOVET 100 (tylosin)/SACOX (salinomycin) Huvepharma EOOD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria.

Therefore, under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 034-085, 035-287, 046-668, 091-668, 108-116, 133-334, 139-473, ( printed page 95026) 140-340, 140-443, 140-947, 141-090, 200-171, 200-569, 200-570, and 200-580, and all supplements and amendments thereto, is hereby withdrawn, effective December 31, 2016.

Elsewhere in this issue of the Federal Register , FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.

Dated: December 20, 2016.

Tracey H. Forfa,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. 2016-31082 Filed 12-23-16; 8:45 am]

BILLING CODE 4164-01-P

Published Document: 2016-31082 (81 FR 95025)